Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma

23 Jul 2018

Abstract excerpt

Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade, but its treatment benefits are limited by acquired resistance, a process that remains incompletely understood. Here we report that an enhancer, located between the promoters of marker of proliferation Ki67 (MKI67) and O6-methylguanine-DNA-methyltransferase (MGMT) genes, is activated in TMZ-resistant patient-derived xenograft...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Glioma Diagnosis and Treatment
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30054476
DOI: 10.1038/s41467-018-05373-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastomaPMID 30054476Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Regulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cellsSemantic proximity Read ↗

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.Semantic proximity Read ↗

Epigenomic perturbation of novel <i>EGFR</i> enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomideSemantic proximity Read ↗

A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastomaSemantic proximity Read ↗

O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme.Semantic proximity Read ↗

YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell lineSemantic proximity Read ↗

O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma ChemotherapySemantic proximity Read ↗

Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patientsSemantic proximity Read ↗

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelSemantic proximity Read ↗

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)Semantic proximity Read ↗

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenograftsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.